AdvisorShares Investments LLC Takes $1.01 Million Position in Grifols, S.A. $GRFS

AdvisorShares Investments LLC acquired a new stake in Grifols, S.A. (NASDAQ:GRFS) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 101,600 shares of the biotechnology company’s stock, valued at approximately $1,012,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Grifols by 2.4% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock worth $427,000 after buying an additional 1,114 shares in the last quarter. Versant Capital Management Inc boosted its stake in Grifols by 39.5% in the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 1,584 shares during the last quarter. Merit Financial Group LLC boosted its position in shares of Grifols by 14.1% in the 3rd quarter. Merit Financial Group LLC now owns 13,978 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 1,728 shares during the last quarter. Savant Capital LLC increased its stake in shares of Grifols by 16.0% in the 3rd quarter. Savant Capital LLC now owns 14,011 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 1,935 shares during the last quarter. Finally, Ascent Group LLC increased its stake in Grifols by 12.5% in the third quarter. Ascent Group LLC now owns 17,597 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 1,951 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. JPMorgan Chase & Co. cut their price target on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, December 8th. Zacks Research downgraded Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, December 5th. Finally, Wall Street Zen raised Grifols from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $10.00.

Grifols Stock Performance

Grifols stock opened at $9.28 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.93 and a current ratio of 2.48. The stock’s fifty day moving average price is $9.10 and its two-hundred day moving average price is $9.47. Grifols, S.A. has a one year low of $6.19 and a one year high of $11.14.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.